January/February 2019

womens_heart_health.png

Ramping up the battle against cardiovascular disease in women represents a golden opportunity to move the needle on mortality.

Kathy

In this magazine’s cover story, we examine the work that still needs to be done to improve women’s heart health. Despite significant progress, too many women aren’t even aware that heart disease is relevant to them, let alone their gender’s leading cause of death.

workplace.png

The moniker is in flux, but patients, clinicians and organizations are embracing the connectedness of virtual hospitals.

sanon.png

Is Interactive Virtual Reality Poised to Deliver a ‘Eureka Moment’ for Cardiology?

cath_lab.png

For-profit and not-for-profit healthcare facilities may value the health of their cath lab employees differently. Without a clear indication of the bottom-line impact, some hospitals may be forgoing protective equipment and sacrificing the long-term health of their workers. Should the C-suite prioritize worker health when allocating investment dollars? 

The Abbott MitraClip is the primary structural heart device used in transcatheter edge-to-edge repairs (TEER) of the mitral valve leaflets. The results of the COAPT trial dropped like a thunderclap Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, with several cardiologists predicting the MitraClip device will have a swift and lasting impact on the treatment of heart failure patients.

Will operators be able to replicate COAPT’s restraint and its outcomes?

heart_device.png

With use of cardiac implantable electronic devices on the rise, experts stress device selection, prophylactic antibiotics, pre-procedural protocols and post-implementation vigilance.

New cholesterol guidelines from the American Heart Association and the American College of Cardiology recommend adding ezetimibe and/or PCSK9 inhibitors to statin therapy for select high-risk patients, and also propose using coronary artery calcium (CAC) scoring as “a tiebreaker” to guide statin decisions for those at intermediate risk of atherosclerotic cardiovascular disease.

Select an Issue
CVB_Jan_Feb_Cover